Bond.az White LogoBond.az Black Logo

Neo Energy Metals shareholders approve all AGM resolutions

Neo Energy Metals shareholders approved all AGM resolutions with over 97% support. The company advances uranium and gold projects in South Africa.

Henry Walker
ByHenry Walker- Senior Editor
|
0

LONDON - Neo Energy Metals plc (LSE:NEO; A2X:NEO) announced that shareholders approved all resolutions at the company’s Annual General Meeting (AGM).

The uranium and gold development company, focused on South Africa, held its AGM earlier today. All resolutions from the Notice of AGM dated April 23, 2026 passed with shareholder approval.

All resolutions received approval rates exceeding 97%, with the highest support at 99.35% for several items, including the re-election of directors Neal Froneman, Sajjad Sabur, John Wallington, Johan Reeder, and Theodoros Botoulas. The appointment of BDO LLP as auditor and receipt of annual reports for fiscal years 2023/24 and 2024/25 also received 99.35% approval.

The company’s Long-Term Incentive Plan received 97.64% approval, while general authority to allot shares passed with 97.30% support.

Following the AGM results, the company stated it will continue progressing the acquisition of the New Beisa Uranium and Gold Project from Sibanye-Stillwater, advancing the implementation assessment programme at New Beisa, and progressing the Henkries Mining Right application process. The company also plans to continue preparations for a planned JSE Main Board listing.

Neal Froneman, Independent Non-Executive Chairman, stated the shareholder support represents an important endorsement of the company’s strategy, governance framework, and long-term development objectives.

Neo Energy Metals is listed on the London Stock Exchange Main Market and the A2X Markets. The company holds two uranium projects in South Africa with a combined JORC- and SAMREC-compliant resource of 31.5 million pounds of uranium and 1.2 million ounces of gold.

More News
Today / 07:43
|
570

Ocado Admits 62,729 Shares to London Stock Exchange

Ocado Group plc admits 62,729 ordinary shares to trading on the London Stock Exchange under the Restricted Share Plan.

0
Today / 07:04
|
876

Avacta reports 2025 results, raises £32.5m for oncology trials

Avacta Group reports 2025 preliminary results, raises £32.5 million for oncology trials. Updates on AVA6103 and AVA6000 programs.

0
Today / 07:02
|
489

Greatland Issues Shares for Employee Incentive Plan

Greatland Resources issues 1.76 million shares for employee incentive plan at A$14.11 each. Shares to be admitted to AIM trading.

0
Today / 06:46
|
625

Kidney Transplant Rejection Test Study Published

Verici Dx's study on kidney transplant rejection test published in Kidney360. PTRA test predicts early acute rejection better than traditional tools.

0
Today / 06:45
|
716

Power Metallic forms Saudi joint venture with Amaar Mining

Power Metallic and Amaar Mining form 50/50 joint venture in Saudi Arabia. Initial funding of $10 million.

0
Today / 06:43
|
917

Bayer's asundexian gets FDA priority review

FDA grants Priority Review to Bayer's asundexian for secondary stroke prevention. Phase III trial results show promise.

0
Today / 06:33
|
784

Orosur Mining Issues 2.85M Shares After RSU Exercise

Orosur Mining issues 2.85M shares after directors and consultants exercise RSUs. Shares to trade on AIM from May 22, 2026.

0
Today / 06:31
|
965

Golden Prospect Moves Portfolio Management to Manulife

Golden Prospect Precious Metals delegates portfolio management to Manulife. New managers Diana Racanelli and Craig Bethune appointed.

0
Today / 06:22
|
948

SSP Group Appoints Candace McGraw to Board

SSP Group appoints Candace McGraw as independent non-executive director. Effective June 1, she brings aviation expertise.

0
Today / 06:01
|
902

CBL-514: New Obesity Data Revealed

Caliway Biopharmaceuticals reveals new data on CBL-514 for obesity. Combination therapy boosts weight loss by 91.5%.

0
Today / 05:21
|
881

Genentech to Present Breast Cancer Data at ASCO Meeting

Genentech will present breast cancer data on giredestrant and other drugs at the 2026 ASCO meeting.

0
Today / 03:43
|
453

Onto Innovation prices $1.3B convertible notes

Onto Innovation prices $1.3 billion convertible senior notes due 2031 at a 50% conversion premium. Interest-free notes with strong liquidity.

0
...